Search PubMed⌕ Search

Biomedical subjects

M Takimoto

Publications and source records attributed to M Takimoto.

At least 127 records · Page 7Linked to original sources
PubMed1982

[Clinical results and pharmacokinetics of cefotaxime in newborn infants].

One full-term newborn infant and 2 premature ones were treated with cefotaxime for the treatment of suspected sepsis and umbilical suppurative inflammation. Pathogenic organisms could not be identified in all cases. A good result was obtained with the case of suspected sepsis. But the other 2 cases were not evaluable because underlying diseases such as massive pulmonary atelectasis or respiratory distress syndrome masked the effects of this agent. Serum levels of cefotaxime in 3 of the 4 cases were determined with bioassay. Time courses of the serum levels in 2 of them resulted in peculiar biphasic disappearance curves. This fact implies the possibility that desacetylation of cefroxime proceeds also in newborns as in adults and that desacetyl metabolite accumulates in the body owing to the premature function of the neonatal kidney.

Bacterial Infections↗
PubMed1982

[Clinical studies with cefmenoxime in the field of pediatrics].

The present study was performed to evaluate the clinical effectiveness and safety of cefmenoxime (CMX), a new cephalosporin antibiotic for injection in the field of pediatrics. Thirty-one cases, including 2 cases with sepsis, 18 cases with respiratory tract infections and 7 cases with urinary tract infections, were given CMX at daily doses of 30 mg/kg to 125 mg/kg divided into 3 or 4 for 3 days to 13 days. Clinical responses were excellent in 16 cases, good in 9 cases and poor in 6 cases, the satisfactory response being 80.6%. No side effects and no abnormal laboratory findings relating to the drug were observed.

Cefmenoxime↗
PubMed1982

[Evaluation of enzyme multiplied immunoassay technique for gentamicin assay. Comparison with bioassay].

To assess an enzyme multiplied immunoassay technique (EMIT) for determination of gentamicin, comparison was done with a microbiological bioassay. Twenty-nine samples from 5 patients and 1 volunteer were assayed by both EMIT and bioassay methods. Concentrations of gentamicin obtained with EMIT were compared with those with bioassay. Statistical calculation resulted in a regression line with a correlation coefficient of 0.9496, a slope of 0.735 and an ordinate intercept of 0.878. To test the specificity of EMIT, serum controls which contain a constant quantity of gentamicin and a variable quantity of ampicillin concomitantly were assayed for gentamicin concentrations by both EMIT and bioassay. This test demonstrated that EMIT is free from interference of ampicillin while bioassay is vulnerable to interference. To conclude, EMIT proved to be a practical alternative to current bioassays for determination of serum gentamicin concentrations.

Adult↗
PubMed1982

[Clinical results of 9, 3"-diacetylmidecamycin dry syrup in the pediatric field (author's transl)].

9, 3"-Diacetylmidecamycin (MOM), a new macrolide antibiotic, was administered to 28 patients: 6 with pharyngitis caused by Group A beta-Streptococcus, 2 with lacunar tonsillitis, 8 with upper respiratory tract infection, 6 with acute bronchitis, 3 with Mycoplasma pneumonia, 1 with primary atypical pneumonia, 1 with pneumonia caused by H. influenzae and 1 with whooping cough. MOM in the form of fine granules was administered at a daily dose of about 20-30 mg/kg divided into 3 doses. Isolated group A beta-Streptococcus strains were eradicated in only 1 out of 6 strain S. One strain of H. influenzae was eradicated. The clinical results could be obtained with 21 cases and the response was excellent in 1 case, good in 7, fair in 3 and poor in 10. Although diarrhea was found in 3 cases during the administration of MOM, it was not clear whether these phenomena were caused by MOM, because of the prevalence of diarrhea among the children treated by us at that time.

Adolescent↗
PubMed1982

[Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy].

An unique combination treatment for cancer patients has been attempted in our department. The treatment consists of 500 rad irradiation of cobalt 60 on the first day and drip infusion of mixture of 50mg adriamycin, 500mg cyclophosphamide and 500mg 5-fluorouracil on the next day. This combination therapy was repeated every 3 weeks. The myocardial intoxication may be a great problem in this therapy. Investigation was performed in 40 cancer patients in order to clarify of Coenzyme Q10 (CoQ10) could show any protecting effect upon the possible myocardial intoxication. All patients were divided into 2 groups; one with CoQ10 of 20 patients, who received CoQ10 of 90mg/day orally and the other without CoQ10 of 20 patients. In the group without CoQ10, cardiothoracic ratio (CTR) and pulse rate increased significantly in all patients and on ECG low voltage of QRS complex was seen in 2 cases, changes of ST-segment, T-wave and appearance of arrhythmia were more than frequent in the group without CoQ10 than that with CoQ10. It is concluded that CoQ10 is effective for protecting the myocardium in this cancer therapy.

Adult↗
PubMed1981

Pulsatile venous flow in extracorporeal circulation.

Effects of pulsatile venous flow upon the microcirculation were investigated in conditions with different venous pressures by using regional perfusion in dog's hind legs. In animals with venous pressure of -18 cmH2O (Collapsed stage), venous pulsation brought about a significant increase in mean oxygen consumption ratio and suppressed a rise of mean resistance ratio significantly. In animals with venous pressure of +2 cmH2O (normal venous pressure stage), the venous pulsation was effective in a rise of mean oxygen consumption ratio but was not effective in suppression of mean resistance ratio. In animals with venous pressure of +10 cmH2O (congestive stage), no effect of venous pulsation was recognized. We suppose that the intermittent elevation of venous pressure by venous pulsation is effective for opening some capillaries in animals with venous pressure below +2 cmH2O.

Animals↗
PubMed1981

[Clinical results of cefotiam in the field of pediatrics (author's transl)].

We have administered cefotiam intravenously to 23 pediatric patients. The daily dose was 13-210 mg/kg. The clinical responses were excellent and good in 20 cases. Excluding 1 case with infectious mononucleosis, the efficacy rate of 90.9% (20/22 cases) was achieved As for side effect, diarrhea and eosinophilia were observed one each in 2 cases. In 2 cases, half lives were 24 and 53 minutes, urinary recovery rates were 88.3 and 91% over 6 hours.

Age Factors↗
PubMed1981

[Clinical results and pharmacokinetics of 6059-S in the field of pediatrics (author's transl)].

6059-S, a new injectable oxacephem antibiotic, has been investigated to give following results. 1. Clinical results Twenty patients were administrated intravenously 20 approximately 124 mg/kg/day of 6059-S for 2 approximately 14 days. Clinical effect was excellent in 5 cases, good in 7, fair in 3, poor in 1, unknown in 3 and except in 1, and efficacy rate was 75%. Side effect was observed only 1 case of discomfort and chill of hand and foot immediately after intravenous injection and no adverse value in laboratory findings was seen. 2. Pharmacokinetics Blood level and urinary excretion of 6059-S single administration were measured in 4 patients with normal renal function and a patient with renal failure. Half life was 1.27 approximately 1.76 hours in 4 patients with normal function and 4.33 hours in a patient with renal failure. Urinary excretion was 43.4 approximately 50.9% up to 4 hours in 2 patients with normal renal function, and it was delayed to 1.0% up to 12.5 hours in a patient with renal failure.

Age Factors↗
PubMed1981

[Clinical results of cefadroxil in children and pharmacokinetics of the drug (author's transl)].

Cefadroxil was administered orally at a daily dose of 30-40 mg/kg to 8 cases of the infection of upper respiratory tract mainly due to beta-hemolytic Streptococcus, and efficacy was obtained in 7 cases, this rate being considered to be satisfactory, though the cases were too few to reach a conclusion. As to pathogens of bacterial infection of upper respiratory tract, beta-hemolytic Streptococcus and Staphylococcus aureus were encountered especially frequently, and in view of antibacterial activity against these 2 bacteria, our results could be approved. Further investigations should be performed carefully, however, to determine if cefadroxil may be a drug of first choice in the treatment of severe bacterial pneumonia and pyothorax. No side effects were observed throughout our treatment, though digestive tract disorders, especially diarrhea, are most frequent in literatures. As to pharmacokinetical characteristic of cefadroxil, almost the same results were obtained to other reports, though our data are insufficient as our experience was limited in only 1 case. Serum levels were determined after 35.7 mg/kg of cefadroxil were administered once orally, and a peak of about 38 mcg/ml appeared 2 hours later, and a high level of about 30 mcg/ml was maintained at 5 hours, though an oral dose was high. Efficacy for large area of bacterial infections may be expected from these serum levels. From urine collected simultaneously, about 74% of cefadroxil was recovered within more than 4 hours. This showed that cefadroxil was well absorbed from digestive tract, and a major part was excreted rapidly through kidney. From the results of our experiment, characteristics of cefadroxil may be summarized as follows. Cefadroxil is absorbed well after oral administration, antibacterial action is fully expected from serum level, a major part is excreted through kidney, and clearance is good. Cefadroxil will be recommended especially for bacterial infections of upper respiratory tract due to beta-hemolytic Streptococcus and Staphylococcus aureus.

Cefadroxil↗